| LAAT (+) | LAAT (−) | P value |
---|---|---|---|
N = 19 | N = 278 | ||
Age (years), mean ± SD | 66 ± 13 | 62 ± 14 | 0.37 |
Age ≥ 75 years, n (%) | 5 (26%) | 55 (20%) | 0.49 |
Male gender, n (%) | 14 (74%) | 176 (63%) | 0.36 |
Hypertension, n (%) | 16 (84%) | 177 (64%) | 0.07 |
Diabetes mellitus, n (%) | 8 (42%) | 73 (26%) | 0.13 |
Congestive heart failure, n (%) | 15 (79%) | 132 (47%) | 0.01 |
History of stroke or TIA, n (%) | 2 (11%) | 27 (10%) | 0.91 |
Aspirin, n (%) | 9 (47%) | 122 (44%) | 0.79 |
Clopidogrel, n (%) | 2 (11%) | 16 (6%) | 0.41 |
Antiplatelet, n (%) | 10 (53%) | 126 (46%) | 0.56 |
Warfarin, n (%) | 15 (79%) | 148 (53%) | 0.03 |
CHADS 2 score, mean ± SD | 2.6 ± 1.2 | 1.9 ± 1.3 | 0.009* |
CHA 2 DS 2 -VASc Score, mean ± SD | 3.5 ± 1.7 | 2.8 ± 1.8 | 0.08* |
CHADS 2 Score ≥ 2, n (%) | 17 (89%) | 158 (57%) | 0.005 |
Duration since first AF episode (days), median (interquartile range) | 691.5 (90–1163) | 162 (4–1249) | 0.28* |
AF type, n (%) | Â | Â | Â |
  • Paroxysmal | 8 (42%) | 153 (55%) | 0.27 |
  • Persistent | 4 (21%) | 58 (21%) | 0.98 |
  • Permanent | 7 (37%) | 67 (24%) | 0.21 |
Creatinine (mg/dL), mean ± SD | 1.6 ± 0.7 | 1.4 ± 1.0 | 0.047* |